Anaconda Biomed S.L., a Barcelona, Spain-based medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, closed €20m in new funding.
The round was led by Asabys Partners from its fund, Sabadell Asabys Health Innovation Investments SCR, SA, with participation from existing investors Ysios Capital, Omega Funds and Innogest, as well as Sabadell Venture Capital.
The company intends to use the funds for clinical studies of its technology, regulatory submissions in international markets, further product development and manufacturing scale-up.
Led by Francois Salmon, CEO, Anaconda Biomed is a medical technology company dedicated to developing next generation thrombectomy systems for the treatment of ischemic stroke. Its flagship product is the Advanced Thrombectomy System, which consists of a delivery catheter, a funnel-shaped aspiration catheter and a stent retriever. When deployed, the funnel self-expands and directly conforms to the artery diameter up to 5mm, locally arresting flow and allowing full thrombus extraction without fragmentation.
The system is designed to deliver significant improvement in revascularization rates at both first and third pass.
Anaconda Biomed has already enrolled 14 patients in a 125-patient first-in-human study.